Drug Profile
Research programme: metabolic disorders therapeutics - DiscoveryBioMed
Latest Information Update: 07 Jul 2022
Price :
$50
*
At a glance
- Originator DiscoveryBioMed
- Class
- Mechanism of Action Adiponectin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 05 Jul 2022 DiscoveryBioMed has been acquired by Eurofins Discovery
- 04 Nov 2017 No recent reports of development identified for research development in Diabetes-mellitus in USA
- 04 Nov 2017 No recent reports of development identified for research development in Obesity in USA